Targeted Oncology - Immunotherapy, Biomarkers, and Cancer …
WEBImmunotherapy Instills Renewed Promise in SCLC. By Tony Berberabe, MPH. September 26th 2024. With immunotherapy-based regimens and novel agents like bispecific antibodies and antibody-drug conjugates, oncologist David R. Spigel, MD, is optimistic about the future of small cell lung cancer treatment.
September 2024 FDA Roundup: Key Decisions Drive Oncology …
WEB1 day ago · In September 2024, the FDA made several significant strides in oncology. Notably, the agency approved a subcutaneous formulation of atezolizumab (Tecentriq) for various cancer types, offering a more convenient administration option for patients. Additionally, ribociclib (Kisqali) was granted approval for …
Breakthrough for Advanced Myeloma? Talquetamab/Teclistamab …
WEB5 days ago · Talquetamab-tgvs (Talvey) plus teclistamab-cqyv (Tecvayli) delivered a high rate of durable responses in patients with triple-class exposed relapsed/refractory multiple myeloma, according to findings from the phase 1b RedirecTT-1 study (NCT04586426) presented at the 21st Annual International Myeloma Society Meeting and Exposition. 1. At the recommended phase 2 regimen (RP2R) of talquetamab at ...
The Targeted Pulse: Adagrasib Bests Docetaxel in Pretreated KRAS …
WEBSep 22, 2024 · Adagrasib Comes Out on Top in Pretreated KRAS G12C-NSCLC Vs Docetaxel. Adagrasib (Krazati) demonstrated significantly better results than docetaxel for patients with previously treated KRAS G12C-mutated non–small cell lung cancer (NSCLC) even in those with existing brain metastases. These findings from the phase 3 KRYSTAL-12 trial (NCT04685135), presented at the 2024 ESMO Congress, evaluated ...
New CAR T Therapy Shows Promise in Treating R/R Multiple …
WEB5 days ago · A new CAR T-cell therapy, durcabtagene autoleucel, showed promising results in treating relapsed/refractory multiple myeloma with high response rates and manageable adverse effects. Durcabtagene autoleucel (PHE885), a BCMA-directed chimeric antigen receptor (CAR) T-cell therapy, produced high response rates with a …
Recent Approvals Signal a Bright Future for Myelodysplastic …
WEBDec 22, 2023 · Ivosidenib . In October 2023, ivosidenib (Tibsovo) was cleared by the FDA for the treatment of IDH1-mutated relapsed or refractory MDS, based on findings from the AG120-C-001 trial (NCT02074839).4 In the study, 18 adult patients with relapsed or refractory MDS with an IDH1 mutation received oral ivosidenib daily on a 28-day cycle. All responses in the trial were complete responses (CRs), and ...
LUNG CANCER - Targeted Oncology
WEBZipalertinib Shows Promise in Heavily Pretreated EGFR Exon 20-Mutated NSCLC. Kristie L. Kahl. September 14th 2024. Zipalertinib appeared safe and effective in the treatment of heavily pretreated patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed on or after amivantamab.
News - Targeted Oncology
WEBFDA Grants FTD to EO-3021 in Advanced Gastric and GEJ Cancers Expressing Claudin 18.2. Jordyn Sava. September 23rd 2024. The FDA granted fast track designation to EO-3021 for the treatment of advanced or metastatic gastric and gastroesophageal junction cancers expressing Claudin 18.2, which have progressed after prior therapy.
The Targeted Pulse: NK-Cell Therapies, T-DXd and ... - Targeted …
WEBApr 7, 2024 · Fam-trastuzumab deruxtecan-nxki (T-DXd) has been used to treat certain cancers and is now showing positive improvement in patients with advanced solid tumors that harbor a HER2 amplification. Data from the DESTINY-PanTumor02 (NCT04482309) trial and the HERALD/EPOC1806 study (UMIN000029315) show promising results across several tumor types ...
Colorectal Cancer - Targeted Oncology
WEBNo Survival Advantage Seen With Ramucirumab and TAS-102 in Metastatic Colorectal Cancer. By Caroline Seymour. September 15th 2024. The combination of ramucirumab with trifluridine/tipiracil failed to show improvements in overall survival vs TAS-102 alone in heavily pretreated metastatic colorectal cancer.